Creative Medical Technology Holdings Announces Key Milestones Regarding ImmCelz® Platform Development

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"text","content":"Independent Studies Validate Enhanced Clinical Grade Cell Production for Patient Use in Multiple Indications at a Fraction of Current Industry Cost\nPHOENIX, March 21, 2023 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company working to revolutionize care through the development of potentially best-in-class regenerative therapeutics, today announced third party validation regarding several aspects of its ImmCelz® (CELZ-100) development program, the Company's cell-free system which has previously been validated to supercharge a patient's own cells to treat a number of immune disorders. \n\n \n \n \n \n \n \n\n \nThese independent studies demonstrated: a 400% increase in the clinical grade cell production yield at the same cost profile as the Company's first generation ImmCelz line; functional suppression of effector T cells, which are a critical concern for patients with autoimmune issues, while still possessing a high number of functional T regulatory cells; and the ability to verify repeated potency of the final ImmCelz®(CELZ-100) product.\nAll experiments were independently conducted and validated on selected human donor patient cells for accuracy and reproducibility. \n\"We are thrilled to have achieved a game changing milestone with our ImmCelz® platform, particularly with respect to the 400% increase of clinical grade, fully functional cells. This substantially reduces the production costs, while allowing for the manufacture of the best clinical product for patients with immune disorders. We believe that this yield increase will enable us to accelerate our clinical applications and encourage potential collaborations utilizing our high quality and cost effective product,\" said Timothy Warbington, CEO.\n\"The ability for our team to safely produce this large number of functional ImmCelz® (CELZ-100) with only one patient sample allows the Company to offer and treat a wider variety of immune patient disorders, especially those that may require multiple dosing strategies which we previously could not perform with the first-generation product. Our current program increases safety for the patient, while improving the quality and effectiveness of our immunotherapy product,\" said Courtney Bartlett, DNP – Director of Clinical Operations. \nAbout ImmCelz®ImmCelz®, which is protected by t...

More updates from Creative Medical Technology Holdings, Inc.